
Niche and needed: German SMEs weather Trump tariffs with specialist tech
The hope is that, in niche areas where American customers have no obvious alternatives, buyers across the Atlantic will just have to accept paying higher prices for their high-tech machines and products.
'The customer in America pays the tariff,' said Thorsten Bauer, co-head of laser maker Xiton Photonics, based in the western city of Kaiserslautern. 'We don't notice a thing.'
Bauer's firm of about 20 workers is in this respect typical of the often family-owned enterprises that make up the German 'Mittelstand', Deutsche Bank executive Jan-Philipp Gillmann said.
'German Mittelstand companies are somewhat protected since they are often very specialised, sometimes the only firm that makes a particular part,' said Gillmann, Deutsche Bank's Head of Corporate Bank Europe.
'The cost of the tariff will often be borne by the consumer.'
Under a framework deal agreed in late July, EU exports are set to face across-the-board US tariffs of 15 per cent from Thursday — higher than traditional duties but much lower than Trump's threatened 30 per cent.
While German corporate titans such as automaker Volkswagen have grabbed headlines by taking tariff hits measured in the billions, many of the smaller firms hope to weather the headwinds.
Brian Fuerderer, head and founder of Microqore Medical, a high-end surgical equipment maker with 32 employees, agreed.
'It's not possible to just copy 'Made in Germany,'' he said. 'There's not much comparable to what we in Germany do when it comes to medical technology.'
He added that US tariffs would have to rise to 30 or even 40 per cent before American customers got cold feet.
'For Volkswagen, for big business, it's hard,' he said. 'But if you have a real niche, something only certain specialists can do, demand will carry on as before.'
'No legal certainty'
The Mittelstand's rugged optimism defies Trump's repeated statements that foreign companies — not American importers or consumers — will pay the tariffs.
That does not mean the levies — and the past months of uncertainty around them — have left the small and medium enterprises entirely unscathed.
The United States is Germany's largest trading partner and Trump's on-again, off-again tariff blitz has already had an impact.
'When all the tariffs started, I made no US sales for three months,' Bauer said. 'You don't spend money if you don't know how things will look in the next six months.'
He hopes the latest agreement fixing duties at 15 per cent, up from a provisional 10 per cent in the lead-up to an August 1 deadline, will at least give American companies the confidence to place orders again.
But he is not entirely sure, pointing to Trump's highly changeable tariff policies.
'There's no legal certainty, basically,' Bauer said. 'I am trying to push up sales in Europe with discounts and things like that, to be less dependent on the international market.'
'Regulating ourselves to death'
About a quarter of Xiton Photonic's sales are exports to the United States and it would be hard to diversify, Bauer said, since his high-tech customers are more often found in Japan, China or America than in Europe.
Wider geopolitical tensions mean there is no easy answer.
'China could equally turn around tomorrow and say: 'We are not importing anything from the EU,'' said Bauer.
'In that case I'd be just another leaf blown about by the wind.'
Fuerderer, whose company makes half its sales in the United States, said that relocating production there could make sense for some firms in the sector over the long term, particularly given high energy costs and burdensome bureaucracy at home.
'The US government wants companies to manufacture in the United States and they have tax breaks, grants and subsidies to make it happen,' he said.
In Europe, by contrast, Fuerderer said 'we are regulating ourselves to death. People are afraid to put money on the table and try something new.' — AFP
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Malay Mail
23 minutes ago
- Malay Mail
Germany freezes Gaza-linked arms exports as Israel moves to seize Gaza City
BERLIN, Aug 8 — The German government will not approve any exports of military equipment that could be used in the Gaza Strip until further notice, Chancellor Friedrich Merz said on Friday in response to Israel's plan to expand its military operations there. Israel's political-security cabinet approved a plan early on Friday to take control of Gaza City, a move expanding military operations despite intensifying criticism at home and abroad over the devastating, almost two-year-old war. Merz said it was Israel's right to disarm Hamas and to seek the release of the Israeli hostages. 'The German government believes that the even tougher military action in the Gaza Strip decided upon by the Israeli cabinet last night makes it increasingly difficult to see how these goals can be achieved,' said Merz in a statement. 'Under these circumstances, the German government will not approve any exports of military equipment that could be used in the Gaza Strip until further notice.' Far-right allies in Prime Minister Benjamin Netanyahu's coalition have been pushing for a total takeover of Gaza as part of his vow to eradicate Hamas militants, though the military has warned this could jeopardise the lives of remaining hostages. The release of the hostages and negotiations for a ceasefire are Germany's top priorities, Merz said, expressing deep concern over the suffering of civilians in the Gaza strip. Germany's parliament said in June that export licences for military equipment to Israel worth €485 million (RM2.4 billion) were granted between October 7, 2023 and May 13, 2025. — Reuters

Malay Mail
2 hours ago
- Malay Mail
Covid vaccine patent fight finally ends: Pfizer-BioNTech to pay CureVac and GSK US$740m plus US sales royalties
FRANKFURT, Aug 8 — American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac US$740 million plus royalties to settle US legal disputes over Covid-19 vaccines, CureVac said Friday. The royalties would amount to a 'single-digit' percentage on sales of Covid-19 vaccines in the United States, CureVac said. The German firm added that it would grant Pfizer and BioNTech non-exclusive licence to make and sell mRNA-based Covid and flu products in the United States. GSK, which since 2020 has worked with CureVac to develop mRNA vaccines for infectious diseases, said that it would receive US$370 million as well as a one-per cent royalty on US sales of flu, Covid and 'related combination mRNA vaccine products'. CureVac sued German rival BioNTech in 2022, arguing that BioNTech had infringed patents relating to mRNA technology in making its blockbuster Comirnaty coronavirus vaccine in colloboration with Pfizer. Unlike traditional vaccines which contain some form of the dead or inactivated target virus,mRNA vaccines contain genetic materials that instruct human cells to make proteins typical of the targeted virus. Since the virus need not be grown in the lab, mRNA vaccines can in theory be developed at scale more quickly than conventional vaccines. The Pfizer-BioNTech vaccine was the first mRNA vaccine approved for use and the first Covid vaccine to receive approval in the West. CureVac's own efforts to make an mRNA-based covid vaccine during the pandemic did not come to fruition. The deal brings the dispute between CureVac and BionNTech to an end ahead of the planned acquisition of CureVac by BioNTech, announced in June. CureVac and BioNTech are still locked in legal disputes in Germany but CureVac said the deal 'set a framework for resolving ongoing patent disputes outside the US'. In March, a German court sided with American pharmaceutical firm Moderna in its claim that BioNTech and Pfizer had broken one of its patents in making its Covid-19 vaccine. — AFP


Free Malaysia Today
2 hours ago
- Free Malaysia Today
Trump's tariffs on Russian oil buyers bring economic, political risks
The White House said that Russian President Vladimir Putin and US President Donald Trump could meet as soon as next week. (Reuters pic) WASHINGTON : From punishing Brazil to trying to curb imports of fentanyl, US President Donald Trump has wielded the threat of tariffs as an all-purpose foreign policy weapon. With a Friday deadline for Russia to agree to peace in Ukraine or have its oil customers face secondary tariffs, Trump has found a novel, but risky, use for his favourite trade tool. The administration took a step toward punishing Moscow's customers on Wednesday, imposing an additional 25% tariff on goods from India over its imports of Russian oil, marking the first financial penalty aimed at Russia in Trump's second term. No order has been signed for China, the top Russian oil importer, but a White House official said on Wednesday that secondary measures that Trump has threatened against countries buying the petroleum were expected today. These are the latest in a string of Trump's tariff threats on non-trade issues such as pressing Denmark to give the US control of Greenland, attempting to stop fentanyl deliveries from Mexico and Canada, and penalising Brazil over what he described as a 'witch hunt' against former president Jair Bolsonaro. While secondary tariffs could inflict pain on the Russian economy – severing a top source of funding for Russian President Vladimir Putin's war effort – they also carry costs for Trump. Oil prices will likely rise, creating political problems for him before next year's US midterm congressional elections. The tariffs would also complicate the administration's efforts to secure trade deals with China and India. For his part, Putin has signaled that Russia is prepared to weather any new economic hardship imposed by the US and its allies. There is 'close to zero chance' Putin will agree to a ceasefire due to Trump's threats of tariffs and sanctions on Russia, said Eugene Rumer, a former US intelligence analyst for Russia who directs the Carnegie Endowment for International Peace's Russia and Eurasia programme. 'Theoretically if you cut off Indian and Chinese purchases of oil that would be a very heavy blow to the Russian economy and to the war effort. 'But that isn't going to happen,' he said, adding that the Chinese have signaled they will keep buying Russia's oil,' Rumer said. The White House did not immediately respond to a request for comment. The Russian embassy in Washington did not immediately respond. New costs for Russia Secondary tariffs would hurt Russia, the world's second leading oil exporter. The West has pressured Russia since late 2022 with a price cap on its oil exports, intended to erode Russia's ability to fund the war. That cap has piled costs on Russia as it forced it to reroute oil exports from Europe to India and China, which have been able to import huge amounts of it at discounted prices. However, the cap also kept oil flowing to global markets. In an early sign that Putin hopes to avoid the tariffs, the White House said that Putin and Trump could meet as soon as next week, following a meeting between US envoy Steve Witkoff and the Russian leader on Wednesday. However, some analysts are sceptical that Moscow is ready to stop the war. Brett Bruen, former foreign policy adviser for former president Barack Obama now head of the Global Situation Room consultancy, cautioned that Putin has found ways to evade sanctions and other economic penalties. 'Even if tariffs and sanctions cut into Russia's revenues, Putin is not under much domestic pressure,' he said. Secondary tariffs, Bruen said, could start to cause some economic pain. 'But the question is whether that really changes Putin's behaviour,' Bruen said. The tariffs could also create new problems for the Trump administration as it pursues sweeping trade deals, especially with India and China. Kimberly Donovan, a former US treasury official, said the tariffs could hamper the US bilateral and trade relationships with India and China. 'You've got two major oil importers that can kind of dig in their heels and push back, knowing what the US needs out of them,' said Donovan, now director of the Economic Statecraft Initiative in the Atlantic Council's GeoEconomics Center. China has demonstrated leverage over the US by cutting off mineral exports and new tariffs would upset a delicate balance negotiated since May to restart those flows critical to a host of US industries. India has leverage over generic pharmaceutical exports and precursor chemicals to the US. Both countries say that oil purchases are a sovereign matter and contend that they are playing by the previous rules, namely the price cap on Russian crude. Russian Roulette Secondary tariffs would raise the cost of imports into the US of products from Russia's customers, giving them an incentive to buy their oil elsewhere. Squeezing the shipments risks spiking fuel prices and inflation around the world that could pose political difficulties for Trump. The month after Moscow's February 2022 invasion, fears of disruptions from Russia pushed international crude prices close to US$130 per barrel, not far from their all-time high of US$147. If India were to stop buying 1.7 million barrels per day (bpd) of Russian crude, about 2% of global supply, world prices would jump from the current US$66, analysts said. JP Morgan analysts said this month it was 'impossible' to sanction Russian oil without triggering a price jump. Any perceived disruptions to Russian shipments could propel Brent oil prices into the US$80s or higher. 'Despite Trump's statements that US producers would step in, it would be unable to quickly ramp up,' they said. Russia could retaliate, including closing the CPC Pipeline from Kazakhstan, which could create a global supply crisis. Western oil firms Exxon, Chevron, Shell, ENI and TotalEnergies ship up to 1 million bpd via CPC, which has total capacity of 1.7 million bpd. Cullen Hendrix, senior fellow at the Peterson Institute for International Economics, said energy shocks are never welcome, especially not amidst a softening housing market and weak job growth. A key question is whether Trump can frame any economic pain as necessary to force Russia to negotiate. 'Of all his tariff gambits, this is the one that could resonate best with voters, at least in principle,' said Hendrix. 'It's also one with massive downside risks,' he said.